Key Takeaways
- • QuantHealth closed a $45M Series B funding round led by Qumra Capital with participation from eight institutional investors including Sanofi Ventures, Bertelsmann Healthcare Investments, and Pitango HealthTech, signaling strong institutional confidence in AI-driven clinical trial simulation technology.
- • The Tel Aviv-based platform has already simulated over 600 clinical trials across 30 indications, demonstrating meaningful market traction and operational validation of its AI methodology for de-risking drug development decisions.
- • Capital will fund enterprise-wide scaling, acceleration of simulation-first clinical development adoption, R&D advancement, workforce expansion, and product portfolio growth—positioning QuantHealth for market leadership in pharmaceutical optimization.
- • QuantHealth's platform enables life sciences organizations to evaluate, optimize, and de-risk clinical and commercial decisions before patient enrollment or capital deployment, addressing a structural inefficiency in drug development economics.
- • The deal reflects investor appetite for enterprise software solutions in regulated life sciences sectors, particularly AI tools that reduce time-to-market and capital expenditure in pharmaceutical development.
Summary
QuantHealth, an Israeli AI-driven clinical trial simulation platform, secured $45 million in Series B funding led by growth-stage investor Qumra Capital. The round featured a consortium of eight institutional investors including Sanofi Ventures, Bertelsmann Healthcare Investments (BHI), Pitango HealthTech, Artofin Venture Capital Fund L.P., GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures. The funding announcement, dated August 4, 2026, reflects sustained institutional interest in AI applications within regulated pharmaceutical development workflows.
Under the leadership of CEO Orr Inbar, QuantHealth has built a platform enabling pharmaceutical and biotechnology organizations to simulate clinical trials using artificial intelligence before committing to patient enrollment or substantial capital deployment. The company reports that its platform has already simulated more than 600 clinical trials across 30 therapeutic indications, providing quantifiable evidence of adoption and utility within the target market. This operational track record strengthens the investment thesis and demonstrates the platform's applicability across diverse therapeutic areas.
The capital infusion will support multiple strategic priorities: scaling enterprise-wide adoption of the simulation-first clinical development model, accelerating R&D capabilities, expanding workforce capacity, and broadening the product portfolio. For pharmaceutical and biotechnology enterprises, the value proposition centers on de-risking and optimizing clinical and commercial decisions through predictive simulation before executing expensive late-stage trials. This capability directly addresses the economic constraints of drug development, where Phase III trials frequently exceed $100M in cost and represent significant sunk capital if patient populations or trial designs prove suboptimal.
The deal positions QuantHealth within the growing market for enterprise software solutions targeting pharmaceutical operations, particularly those leveraging machine learning to improve decision-making in highly regulated environments. The participation of Sanofi Ventures—representing one of the world's largest pharmaceutical companies—and BHI—the investment arm of Bertelsmann, a diversified conglomerate with healthcare exposure—signals both corporate and financial validation of the company's technology and market opportunity. The funding round reflects investor conviction that AI-enabled clinical simulation represents a material efficiency improvement for the global drug development pipeline.
Under the leadership of CEO Orr Inbar, QuantHealth has built a platform enabling pharmaceutical and biotechnology organizations to simulate clinical trials using artificial intelligence before committing to patient enrollment or substantial capital deployment. The company reports that its platform has already simulated more than 600 clinical trials across 30 therapeutic indications, providing quantifiable evidence of adoption and utility within the target market. This operational track record strengthens the investment thesis and demonstrates the platform's applicability across diverse therapeutic areas.
The capital infusion will support multiple strategic priorities: scaling enterprise-wide adoption of the simulation-first clinical development model, accelerating R&D capabilities, expanding workforce capacity, and broadening the product portfolio. For pharmaceutical and biotechnology enterprises, the value proposition centers on de-risking and optimizing clinical and commercial decisions through predictive simulation before executing expensive late-stage trials. This capability directly addresses the economic constraints of drug development, where Phase III trials frequently exceed $100M in cost and represent significant sunk capital if patient populations or trial designs prove suboptimal.
The deal positions QuantHealth within the growing market for enterprise software solutions targeting pharmaceutical operations, particularly those leveraging machine learning to improve decision-making in highly regulated environments. The participation of Sanofi Ventures—representing one of the world's largest pharmaceutical companies—and BHI—the investment arm of Bertelsmann, a diversified conglomerate with healthcare exposure—signals both corporate and financial validation of the company's technology and market opportunity. The funding round reflects investor conviction that AI-enabled clinical simulation represents a material efficiency improvement for the global drug development pipeline.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.